Published in Health Insurance Law Weekly, August 14th, 2005
According to recent research from the United States, "Peptidomimetics of HIV-1 gp41 sequences required for membrane fusion are potent inhibitors of HIV-1 entry. We hypothesize that expression of a membrane-bound gp41-derived fusion inhibitor will confer HIV-1 resistance to primary CD4 T cells. Efficient gene delivery and stable expression of a membrane-bound gp41-derived fusion inhibitor to primary CD4 T cells was accomplished using a self-inactivating lentiviral vector."
"A potent antiviral effect was observed when transduced...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Insurance Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.